Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday

Heron Therapeutics (NASDAQ:HRTX) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $39.5330 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Heron Therapeutics Price Performance

Heron Therapeutics stock opened at $1.21 on Thursday. The firm has a market capitalization of $221.87 million, a PE ratio of -13.44 and a beta of 1.25. Heron Therapeutics has a 52 week low of $1.00 and a 52 week high of $2.68. The firm’s 50-day simple moving average is $1.33 and its 200 day simple moving average is $1.29. The company has a quick ratio of 1.78, a current ratio of 2.56 and a debt-to-equity ratio of 19.89.

Analyst Ratings Changes

HRTX has been the topic of several recent research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Heron Therapeutics in a research report on Friday, January 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Heron Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.50.

Institutional Trading of Heron Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Rubric Capital Management LP increased its stake in shares of Heron Therapeutics by 3.3% during the 4th quarter. Rubric Capital Management LP now owns 30,046,828 shares of the biotechnology company’s stock valued at $39,061,000 after acquiring an additional 946,100 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Heron Therapeutics by 9.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 11,185,325 shares of the biotechnology company’s stock worth $14,541,000 after acquiring an additional 946,100 shares during the last quarter. Velan Capital Investment Management LP grew its holdings in Heron Therapeutics by 25.3% in the third quarter. Velan Capital Investment Management LP now owns 8,753,290 shares of the biotechnology company’s stock valued at $11,029,000 after purchasing an additional 1,766,546 shares during the period. Millennium Management LLC increased its position in Heron Therapeutics by 2,785.2% during the fourth quarter. Millennium Management LLC now owns 7,169,908 shares of the biotechnology company’s stock worth $9,321,000 after purchasing an additional 6,921,405 shares during the last quarter. Finally, Tang Capital Management LLC raised its stake in Heron Therapeutics by 81.2% during the fourth quarter. Tang Capital Management LLC now owns 6,250,000 shares of the biotechnology company’s stock worth $8,125,000 after purchasing an additional 2,800,000 shares during the period. 80.01% of the stock is owned by institutional investors and hedge funds.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.